| A Study of Longer Interval of IVT IBI302 in Subjects With nAMD (NCT05403749) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-06-29 |
| TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration (NCT05461339) | BioDlink Biopharm Co., Ltd. | 2022-06-28 |
| Safety and Efficacy of AM712 in Patients with NAMD (NCT05345769) | AffaMed Therapeutics Limited | 2022-04-28 |
| Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting (NCT05266495) | Novartis Pharmaceuticals | 2022-04-13 |
| Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) (NCT05275205) | Unity Biotechnology, Inc. | 2022-03-02 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants (NCT05105607) | Ashvattha Therapeutics, Inc. | 2022-01-11 |
| Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study (NCT06021366) | Novartis Pharmaceuticals | 2022-01-07 |
| Maximum Treatment Interval With Aflibercept T&E (NCT05342857) | Shin Kong Wu Ho-Su Memorial Hospital | 2022-01-01 |
| A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (NCT04853251) | Genentech, Inc. | 2021-12-14 |
| Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD) (NCT05831007) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2021-12-06 |
| Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up (NCT06178770) | Novartis Pharmaceuticals | 2021-12-01 |
| Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice (NCT05112835) | Novartis Pharmaceuticals | 2021-11-19 |
| Evaluation of IBI302 Injection in nAMD or DME (NCT05961007) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-11-18 |
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NCT05112861) | Outlook Therapeutics, Inc. | 2021-11-15 |
| The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT (NCT05202587) | Notal Vision Inc. | 2021-11-10 |
| Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment in Neovascular Age-related Macular Degeneration Using Artificial Intelligence (NCT05208931) | The S.N. Fyodorov Eye Microsurgery State Institution | 2021-11-01 |
| Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) (NCT04304755) | Oslo University Hospital | 2021-10-25 |
| Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (NCT04774926) | Novartis Pharmaceuticals | 2021-10-15 |
| Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study (NCT05131646) | Clearside Biomedical, Inc. | 2021-10-08 |
| Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study (NCT05281042) | Notal Vision Inc. | 2021-09-13 |
| Regulatory Post-Marketing Surveillance Study for Brolucizumab (NCT04985487) | Novartis Pharmaceuticals | 2021-08-18 |
| Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (NCT04989699) | Ocular Therapeutix, Inc. | 2021-07-28 |
| Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (NCT04864834) | Sandoz | 2021-05-12 |
| A Study of IBI302 in Patients With nAMD (NCT04820452) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-04-28 |
| A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (NCT04777201) | Hoffmann-La Roche | 2021-04-19 |
| OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (NCT04757636) | Opthea Limited | 2021-03-12 |
| OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (NCT04757610) | Opthea Limited | 2021-03-12 |
| A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (NCT04662944) | Novartis Pharmaceuticals | 2021-02-23 |
| RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) (NCT04832724) | AbbVie | 2021-02-22 |
| A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration (NCT04239027) | Novartis Pharmaceuticals | 2021-01-26 |
| A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration (NCT04684394) | Gemini Therapeutics, Inc. | 2020-12-29 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (NCT04704921) | AbbVie | 2020-12-29 |
| Russian Registry of Patients With nAMD (NCT04935411) | Novartis Pharmaceuticals | 2020-12-20 |
| An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (NCT04597632) | Novartis Pharmaceuticals | 2020-12-16 |
| Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD (NCT04626128) | Clearside Biomedical, Inc. | 2020-12-15 |
| Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] (NCT04645212) | Adverum Biotechnologies, Inc. | 2020-12-14 |
| Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (NCT04264819) | Novartis Pharmaceuticals | 2020-12-14 |
| A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). (NCT04641234) | Bayer | 2020-12-11 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients (NCT04635800) | Novartis Pharmaceuticals | 2020-12-10 |
| Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections (NCT04563299) | Retina Vitreous Associates of Florida | 2020-12-09 |
| Single In-Clinic Encounter With the Notal Vision Home OCT (NCT04642183) | Notal Vision Inc. | 2020-11-16 |
| Time Efficiency Comparison of Two IntraVitreal Injection Techniques (NCT04455399) | Peregrine Eye and Laser Institute | 2020-11-09 |
| Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration (NCT04537884) | Unity Biotechnology, Inc. | 2020-10-08 |
| A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders (NCT04516278) | Outlook Therapeutics, Inc. | 2020-10-01 |
| Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD (NCT04690556) | Lupin Ltd. | 2020-09-14 |
| The Sahlgrenska Anti-VEGF Study (NCT04101877) | Vastra Gotaland Region | 2020-09-03 |
| Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration (NCT04422899) | AiViva BioPharma, Inc. | 2020-08-28 |
| A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) (NCT04480463) | Sam Chun Dang Pharm. Co. Ltd. | 2020-08-13 |
| Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (NCT04423718) | Bayer | 2020-08-11 |
| Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration (NCT04522167) | Bioeq GmbH | 2020-07-21 |
| Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept (NCT04287348) | Vista Klinik | 2020-07-20 |
| A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT04450329) | Samsung Bioepis Co., Ltd. | 2020-06-23 |
| Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients (NCT04370379) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-05-28 |
| Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD (NCT04058535) | Alteogen, Inc. | 2020-02-05 |
| A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD (NCT04331730) | Alkahest, Inc. | 2020-01-28 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration (NCT04047472) | Novartis Pharmaceuticals | 2019-11-29 |
| Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration (NCT05587062) | Cinnagen | 2019-10-01 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (NCT03953079) | Graybug Vision | 2019-09-26 |
| Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography (NCT03909425) | Moorfields Eye Hospital NHS Foundation Trust | 2019-09-02 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03834753) | Outlook Therapeutics, Inc. | 2019-06-25 |
| A Study Assessing AR-13503 Implant in Subjects With nAMD or DME (NCT03835884) | Aerie Pharmaceuticals | 2019-06-24 |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (NCT03999801) | AbbVie | 2019-05-31 |
| Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration (NCT03699618) | Johns Hopkins University | 2019-05-29 |
| Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration (NCT03930641) | Novartis Pharmaceuticals | 2019-05-23 |
| A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration (NCT03814291) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-04-15 |
| CLN-0046: Treatment of AMD Subjects With OTX-TKI (NCT03630315) | Ocular Therapeutix, Inc. | 2019-02-18 |
| Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration (NCT03777254) | RemeGen Co., Ltd. | 2019-01-07 |
| Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment (NCT03833830) | Dr. med. Katja Hatz | 2019-01-07 |
| Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (NCT03630952) | Chengdu Kanghong Biotech Co., Ltd. | 2018-12-21 |
| Post Intravitreal Injection Topical NSAID vs. Patching (NCT03918590) | The New York Eye & Ear Infirmary | 2018-12-03 |
| ADVM-022 Intravitreal Gene Therapy for Wet AMD (NCT03748784) | Adverum Biotechnologies, Inc. | 2018-11-14 |
| Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) (NCT03216538) | Feramda | 2018-10-08 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03844074) | Outlook Therapeutics, Inc. | 2018-10-01 |
| Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) (NCT03577899) | Chengdu Kanghong Biotech Co., Ltd. | 2018-09-25 |
| Extension Study for the Port Delivery System With Ranibizumab (Portal) (NCT03683251) | Hoffmann-La Roche | 2018-09-20 |
| A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (NCT03677934) | Hoffmann-La Roche | 2018-09-12 |
| Intense Treatment Regimen With Intravitreal Aflibercept Injection (NCT03594461) | Vitreous -Retina- Macula Consultants of New York | 2018-09-11 |
| Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (NCT03468296) | Tennessee Retina | 2018-04-01 |
| Pegcetacoplan (APL-2) in Neovascular AMD (NCT03465709) | Apellis Pharmaceuticals, Inc. | 2018-02-14 |
| A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (NCT03387566) | Huabo Biopharm Co., Ltd. | 2018-02-08 |
| Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) Therapy (NCT03065907) | Johns Hopkins University | 2018-01-15 |
| Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD (NCT03386474) | Novartis Pharmaceuticals | 2018-01-15 |
| A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD (NCT03345082) | Opthea Limited | 2017-11-06 |
| A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration (NCT03021785) | Jiangsu T-Mab Biopharma Co.,Ltd | 2017-10-18 |
| ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) (NCT03362190) | Ophthotech Corporation | 2017-10-11 |
| Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial (NCT03066258) | REGENXBIO Inc. | 2017-03-29 |
| Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD (NCT05571267) | IVERIC bio, Inc. | 2016-10-20 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema (NCT02867735) | Novartis Pharmaceuticals | 2016-09-21 |
| Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration (NCT02843490) | Johannes Gutenberg University Mainz | 2016-08-05 |
| Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor (NCT03679156) | Hospital Hietzing | 2016-05-30 |
| Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD (NCT02457026) | Duke University | 2016-01-01 |
| Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (NCT02613559) | Jiangsu T-Mab Biopharma Co.,Ltd | 2015-11-01 |
| Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration (NCT02507388) | Alcon Research | 2015-08-24 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (NCT02434328) | Alcon Research | 2015-07-28 |
| SD-OCT Angiography (NCT02510885) | Duke University | 2015-07-01 |
| Photodynamic Therapy for PDA in NV AMD (NCT02452840) | Duke University | 2015-05-11 |
| Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (NCT02418754) | Regeneron Pharmaceuticals | 2015-05-05 |
| Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD (NCT02461771) | Apellis Pharmaceuticals, Inc. | 2015-01-28 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (NCT02307682) | Alcon Research | 2014-12-08 |
| Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD (NCT02367365) | Duke University | 2014-12-01 |